Granulocyte-macrophage colony-stimulating factor and IL-5 activate mitogen-activated protein kinase through Jak2 kinase and phosphatidylinositol 3-kinase inhuman eosinophils - 10/09/11
Abstract |
Mitogen-activated protein (MAP) kinases are activated by the sequential activation of Ras, Raf, and MEK (MAP kinase kinase) and regulate a wide variety of cell functions. To determine the kinase cascade for granulocyte-macrophage colony-stimulating factor (GM-CSF)– and IL-5–induced MAP kinase activation in eosinophils, we studied the effect of inhibitors of Jak2 kinase, tyrosine kinases, phosphatidylinositol 3-kinase, and protein kinase C on GM-CSF– and IL-5–induced MAP kinase activation in human eosinophils. GM-CSF and IL-5 activated 40, 42, and 44 kilodalton MAP kinase isoforms in eosinophils. This was indicated by the electrophoretic mobility shift of the three isoforms of MAP kinase in immunoblotting with anti-MAP kinase antibody and also by in-gel MAP kinase assay. MAP kinase activation was time- and dose-dependent, becoming maximal 3 to 15 minutes after stimulation. A Jak2 kinase inhibitor AG-490, a tyrosine kinase inhibitor genistein, and a phosphatidylinositol 3-kinase inhibitor wortmannin inhibited GM-CSF– and IL-5–induced MAP kinase activation in eosinophils, whereas a protein kinase C inhibitor staurosporine had a weak inhibitory effect. Furthermore, AG-490 and genistein prevented GM-CSF–induced tyrosine phosphorylation of Jak2 kinase in eosinophils. Taken together, these results indicate that GM-CSF and IL-5 activate MAP kinases through the signaling pathway of Jak2 kinase–tyrosine phosphorylated β chain–phosphatidylinositol 3-kinase–Ras in eosinophils. (J Allergy Clin Immunol 1997;100:S45-51.)
Le texte complet de cet article est disponible en PDF.Keywords : granulocyte-macrophage colony-stimulating factor, IL-5, mitogen-activated protein kinase, Jak2 kinase, phosphatidylinositol 3-kinase, eosinophils
Abbreviations : ATP, GM-CSF, MACS, MAP, MEK, PI, PMA, PVDF, SDS, SDS-PAGE, STAT
Plan
| From the Department of Internal Medicine, Chiba University School of Medicine. |
|
| Supported in part by grants from the Ministry of Education, Science and Culture, Japan and by grants from Sandoz Pharmaceutical Co., Japan. |
|
| Reprint requests: Itsuo Iwamoto, MD, Department of Internal Medicine, Chiba University School of Medicine, 1-8-1 Inohana, Chiba City, Chiba 260 Japan. |
|
| 1/0/85416 |
Vol 100 - N° 6S
P. S45-S49 - décembre 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
